Reinfjell Trude, Tremolada Marta, Zeltzer Lonnie K
Department of Psychology, Norwegian University of Science and TechnologyTrondheim, Norway; Department of Child and Adolescent Psychiatry, St. Olavs University HospitalTrondheim, Norway.
Department of Developmental and Social Psychology, University of Padua Padua, Italy.
Front Psychol. 2017 Mar 10;8:253. doi: 10.3389/fpsyg.2017.00253. eCollection 2017.
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and failure of conventional treatments for cancer in childhood or as a first line treatment for some high-risk cancers. Since hematopoietic stem cells can be found in the marrow (previously called a bone marrow transplantation) or periphery, we refer to HSCT as inclusive of HSCT regardless of the origin of the stem cells. HSCT is associated with adverse side effects, prolonged hospitalization, and isolation. Previous studies have shown that survivors of HSCT are at particularly high risk for developing late effects and medical complications, and thus, in addition to survival, quality of life in survivors of HSCT is an important outcome. This review summarizes and distills findings on the health-related quality of life (HRQOL) of long-term childhood cancer survivors of HSCT and examines significant sociodemographic, medical, disease and treatment correlates of HRQOL, as well as the methodology of the studies (instruments, type of studies, timing of assessment, type of transplantation). Because previous reviews covered the studies published before 2006, this review searched three databases published between January, 2006, and August, 2016. The search identified nine studies, including 2 prospective cohort studies and 7 cross-sectional studies. All studies reported a follow-up time of >5 years. The review found that HRQOL is significantly impacted over time following childhood HSCT, with salient correlates of HRQOL found to be presence of a severe chronic health or major medical condition, graft vs. host disease (GVHD), or pain. Continual evaluation of HRQOL must be integrated into long-term follow-up after childhood HSCT, and intervention should be offered for those survivors with poor HRQOL. Longitudinal studies should be emphasized in future research to allow for predictor models of resilience and poor HRQOL.
造血干细胞移植(HSCT)是儿童癌症疾病复发且常规治疗失败后的标准治疗方法,或作为某些高危癌症的一线治疗方法。由于造血干细胞可在骨髓中找到(以前称为骨髓移植)或外周血中找到,因此无论干细胞来源如何,我们都将HSCT视为包含所有造血干细胞移植类型。HSCT会带来不良副作用、延长住院时间并需要隔离。先前的研究表明,HSCT幸存者发生晚期效应和医疗并发症的风险特别高,因此,除了生存之外,HSCT幸存者的生活质量也是一个重要的结果。本综述总结并提炼了关于HSCT长期儿童癌症幸存者健康相关生活质量(HRQOL)的研究结果,并研究了HRQOL的重要社会人口统计学、医学、疾病和治疗相关因素,以及研究方法(工具、研究类型、评估时间、移植类型)。由于先前的综述涵盖了2006年之前发表的研究,本综述检索了2006年1月至2016年8月期间发表的三个数据库。检索到九项研究,包括两项前瞻性队列研究和七项横断面研究。所有研究报告的随访时间均>5年。综述发现,儿童HSCT后随着时间推移,HRQOL受到显著影响,发现HRQOL的显著相关因素为存在严重慢性健康问题或重大疾病、移植物抗宿主病(GVHD)或疼痛。必须将HRQOL的持续评估纳入儿童HSCT后的长期随访中,对于HRQOL较差的幸存者应提供干预措施。未来研究应强调纵向研究,以便建立恢复力和HRQOL较差的预测模型。